Tai Long Pharmaceutical industry to enter the heart and cerebrovascular products prospects or not optimistic

Tai Long Pharmaceutical (600222) September 16 Night Notice, the Board of Trustees after analysis and research, the company decided to anti-tumor and treatment of cardio-cerebral vascular products as a new direction, product dosage forms to small volume injection and freeze dry powder needle, research and development methods to take the form of in-depth cooperation with professional research institutions. In the clear of the above research and development direction, the company will also create a corresponding small volume injection and freeze dry powder needle workshop to meet the product development and declaration conditions, and for future production and operation ready. At the same time, in view of the company has made clear the direction of research and development, the company intends to purchase 4 million yuan to buy Beijing Kang Cao Pharmaceutical Technology Co., Ltd. has a ⅱa sulfonate raw materials and frozen Powder needle (specification: 20mg;40mg) Project technical research results. Injection of Tanshinone ⅱa sulfonate (lyophilized powder Needle) is based on tanshinone ⅱa sulfonic acid Sodium Injection (small volume injection) as the basis of new drug formulations, Tanshinone ⅱa sulfonate Injection (small volume injection) is a common drug for the treatment of coronary heart disease, angina pectoris and myocardial infarction. The investment will enrich the company's product reserves, allowing the company to increase the treatment of cardio-cerebrovascular diseases of drugs. At present, Tai Lung Pharmaceutical main product dosage form for oral liquid, solid preparation and large capacity injection, the main product for Shuanghuanglian Oral Liquid series, double gold mixture, the Hubble film and so on. The report showed that the company achieved net profit of 13.9062 million yuan in the first half, an increase of 55.12% per share, 0.0337 yuan. During the reporting period, the company realized operating income of 605 million yuan, an increase of 27.24%, mainly because of Tai Lung pharmaceutical industry this year continue to promote new marketing model, increase marketing efforts, optimize product structure. Cardio-Cerebrovascular disease is a series of cardiovascular and cerebrovascular related diseases, including hypertension, hyperlipidemia, coronary heart disease, heart rate disorders, myocardial infarction, heart failure and stroke. The market scale of cardio-cerebrovascular drugs continues to grow. There are more than 200 million patients with cardio-cerebrovascular disease in China, and the incidence rate is increasing in recent years. According to IMS Statistics, 2011 China's cardiovascular and cerebrovascular drugs, including antithrombotic drugs market scale of more than 56 billion yuan. Analysts said that at present there are many listed companies have targeted cardio-cerebrovascular drugs, including in this industry has the advantage of enterprises, Tai Lung pharmaceutical industry is just involved in the future is not too optimistic. (Zhong Zhimin)